Business Wire

Harbert Management Corporation and Claret Capital Partners Announce Close of Transaction

29.10.2020 14:39:00 EET | Business Wire | Press release

Share

Harbert Management Corporation (“HMC”) and Claret Capital Partners Limited (“Claret”), a company formed by David Bateman and Johan Kampe, are pleased to announce the closing of a transaction by which Claret has assumed full ownership and control of the general partners of Harbert European Growth Capital (“HEGC”) investment funds, including Harbert European Growth Capital Fund I, L.P. (“HEGCF I”), Harbert European Growth Capital Fund II, SCSp (“HEGCF II”) and the newly launched Harbert / Claret European Growth Capital Fund III, SCSp (“HEGCF III”). HMC and its affiliates will remain investors in HEGCF I and HEGCF II, and HMC’s interests continue to be aligned with investors in HEGCF I and HEGCF II.

In connection with the transaction, Claret is hiring the entire HEGC investment team, assuming the lease for their current office space in London and acquiring related assets from HMC. Johan Kampe, Managing Partner of Claret, said “Over the past seven years, we have built a fantastic team of investment professionals who have proven to be outstanding stewards of the capital invested through HEGCF I and HEGCF II. This investment team will remain the same, and their activities are expected to continue seamlessly as we commence investing HEGCF III.”

As a result of the transaction, Claret now manages, or has arranged for the third party management of, the HEGC funds commencing October 26, 2020. While HMC no longer serves as the investment manager for HEGCF I and HEGCF II, HMC will continue to provide operational support and assistance to Claret consistent with past practices pursuant to a services agreement. David Bateman, Managing Partner of Claret, said “We are grateful for our seven year partnership with HMC, during which time we learned a great deal about managing investment funds. This experience has prepared us well to take the next step in the evolution of the HEGC strategy and consolidate investment and operational functions within Claret, of course working with our chosen third party managers, and with the continuing support of HMC. We are very excited to be taking this step.”

HMC and the principals of Claret formed HEGCF I in partnership together in 2013, and over the past seven years have built one of the preeminent providers of venture and growth debt to SMEs in Europe, with over €400 million invested in over 120 European SMEs and recognition as Investor All Stars – 2019 Specialty Debt Provider of the Year. Raymond Harbert, Chief Executive Officer of HMC, said “As we look back over the last seven years, we are proud of what we have accomplished together with the Harbert European Growth Capital strategy, and we remain very pleased with our investments in the HEGC funds. However, as I look forward into the future, it is clear to me that the time is right for David and Johan to take this strategy into the future from Europe, independent of HMC, but with HMC’s full support.”

For More Information
Visit: www.claret-capital.com

###

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lyall Davenport
+44(0) 7481 492996

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 02:00:00 EEST | Press release

Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for people living with FOP, bringing a new treatment option to adult and pediatric patients living with this devastating disease,” said Chris Peetz, Chief Executive Officer at Mirum. “At Mirum, we are driven to serve rare disease communities where the unmet need is significant and the opportunity to make a difference is profound. The approval of Atebrioz reflects what can be achieved when industry, researchers

Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 22:19:00 EEST | Press release

At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where Digital Reef will purchase verified environmental assets generated by Oreasoc, supporting the development of low-carbon data centres mitigating their environmental footprint through the protection of high-integrity natural ecosystems across the South American Amazon, whilst advancing sustainable economic development. AI and data centre demand is driving rapid growth, with the International Energy Agency project

NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 16:00:00 EEST | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata from data and enables metadata services to scale independently, creating a foundation for AI infrastructure capable of supporting trillions of files, exabyte-scale environments, and massively pa

MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 15:57:00 EEST | Press release

MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity, technology, infrastructure, execution, market access and tailored client solutions within an integrated financial ecosystem. The second award acknowledg

Croma-Pharma Introduces saypha ® volume prime Lidocaine25.9.2026 15:04:00 EEST | Press release

Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine, Croma-Pharma further strengthens its product range, reflecting the company's long-standing commitment to scientific excellence and continuous product innovation, and provid

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye